Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine Combined With Conventional Therapy in Multiple Myeloma
NCT05802992Phase 3Unknown
- Sponsor
- Affiliated Hospital of Nantong University
- Start
- Mar 2022
- Primary completion
- Dec 2024
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of colchicine in multiple myeloma (MM), sponsored by Affiliated Hospital of Nantong University. Status: unknown.
02
Drugs
colchicine
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05802992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05802992.